EyePoint, Inc. (EYPT) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $11.90, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $37.00 vs price $11.77 — ratio 3.1×). Rejected, falling back to technical TP.; Market cap $0.96B below $1B minimum.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product... Read more
Hold if already holding. Not a fresh buy at $11.90, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $37.00 vs price $11.77 — ratio 3.1×). Rejected, falling back to technical TP.; Market cap $0.96B below $1B minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $0.96B below $1B minimum. Not in investable universe. Score 5.1/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 57d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-10Recent Developments — EyePoint, Inc.
Latest news
- NEWS RBC Capital Maintains Outperform on EyePoint, Lowers Price Target to $37 — benzinga May 7, 2026 positive
- NEWS Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
- NEWS Eyepoint Reported $223M Of Cash And Investments As Of March 31, 2026, With Runway Into Q4 2027 — benzinga May 6, 2026 positive
- NEWS EyePoint Pharmaceuticals Q1 EPS $(0.99) Misses $(0.80) Estimate, Sales $696.000K Beat $352.833K Estimate — benzinga May 6, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 6.5% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $11.90, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $37.00 vs price $11.77 — ratio 3.1×). Rejected, falling back to technical TP.; Market cap $0.96B below $1B minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $0.96B below $1B minimum. Not in investable universe. Target $13.75 (+15.5%), stop $10.95 (−8.7%), A.R:R 0.0:1. Score 5.1/10, moderate confidence.
Take-profit target: $13.75 (+16.8% upside). Target $13.75 (+15.5%), stop $10.95 (−8.7%), A.R:R 0.0:1. Stop-loss: $10.95.
DATA_ISSUE: analyst_target_implausible (raw $37.00 vs price $11.77 — ratio 3.1×). Rejected, falling back to technical TP.; Market cap $0.96B below $1B minimum.
EyePoint, Inc. trades at a P/E of N/A (forward -4.0). TrendMatrix value score: 5.0/10. Verdict: Hold.
18 analysts cover EYPT with a consensus score of 4.3/5. Average price target: $37.
What does EyePoint, Inc. do?EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious...
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.